1. Male or female, able and willing to provide a written informed consent

2. Diagnosed with type 2 diabetes ≥ 90 days；

3. On stable once-daily dose of basal insulin alone or in combination with metformin and/or SGLT2 inhibitor ≥ 90 days;

4. HbA1c was 7.5%~11.0% (both inclusive);

5. Body Mass Index (BMI) ≥22 kg/m2 at screening.

1. A history of type 1 diabetes, specific diabetes, or secondary diabetes;

2. Have a history of severe hypoglycemia within t180 days prior to screening;

3. History of acute cardiovascular and cerebrovascular diseases within 180 days prior to screening；

4. Have a history of malignancy within 5 years;

5. Known or suspected allergy or intolerance to the investigational medicinal products or related products;

6. Participation in any clinical trial of an approved or non-approved investigational product/treatment within the last 90 days;

7. Any conditions that the Investigator judges might not be suitable to participate in the trial.